Acrivon Therapeutics is a technology company.
Acrivon Therapeutics is a technology company.
Acrivon Therapeutics has raised $100.0M across 1 funding round.
Acrivon Therapeutics has raised $100.0M in total across 1 funding round.
Acrivon Therapeutics has raised $100.0M in total across 1 funding round.
Acrivon Therapeutics's investors include MPM Capital, RA Capital.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology medicines, leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop a drug pipeline and companion diagnostics called OncoSignature tests.[1][2] The AP3 platform analyzes phosphoproteomics to match therapies with patients based on active tumor-driving mechanisms, independent of genetic alterations, accelerating clinical development and improving outcomes in oncology.[1][2] Its lead program, ACR-368 (prexasertib), a CHK1/2 inhibitor in-licensed from Eli Lilly, is in Phase 2 trials showing durable responses in solid cancers; the pipeline also includes ACR-2316, a selective WEE1/PKMYT1 inhibitor in clinical stages, and a preclinical cell cycle program.[1][2]
Acrivon serves oncology patients with hard-to-treat solid tumors, solving the problem of ineffective broad-spectrum cancer therapies by enabling highly specific patient selection through proteomics-driven diagnostics, which boosts trial success rates and treatment efficacy.[1][2] Growth momentum stems from advancing multiple DDR and cell cycle programs, with ACR-368 demonstrating clinical activity, positioning the company as a leader in proteomics-based precision medicine.[1][2]
Acrivon Therapeutics emerged from breakthroughs in phosphoproteomics technology, though specific founding details like exact year or founders are not detailed in available sources; it operates as a clinical-stage entity with a focus on oncology innovation.[1][2] The core idea crystallized around the AP3 platform, a proprietary tool for mapping tumor signaling pathways to predict drug responses, leading to the development of OncoSignature companion diagnostics.[1][2] Pivotal early traction came from in-licensing ACR-368 (prexasertib) from Eli Lilly, which showed evidence of durable responses in Phase 2 trials for solid cancers, validating the platform's patient-selection approach and fueling pipeline expansion into WEE1/PKMYT1 and other cell cycle targets.[1][2]
The company's culture emphasizes values like purpose, rigor, passion, accountability, perseverance, creativity, and teamwork, attracting pioneers to build transformative oncology solutions.[1]
Acrivon rides the precision oncology wave, shifting from genomics to proteomics and phosphoproteomics for deeper tumor signaling insights, addressing limitations of genetic-only approaches in heterogeneous cancers.[1][2] Timing aligns with surging demand for biomarker-driven therapies amid rising cancer incidence and DDR/cell cycle targets' prominence in immuno-oncology resistance.[1][2] Market forces like advanced sequencing costs dropping and AI-enhanced proteomics favor scalable platforms like AP3, while regulatory emphasis on companion diagnostics boosts adoption.[1][2] Acrivon influences the ecosystem by pioneering proteomics-guided patient stratification, potentially setting standards for trial efficiency and inspiring biopharma to integrate multi-omics.
Acrivon is poised for Phase 2 readouts on ACR-368 and ACR-2316 advancement, with AP3 expansion driving new indications and partnerships.[1][2] Trends like multi-omics integration and AI-proteomics will amplify its edge, potentially evolving it into a diagnostics-drug powerhouse amid oncology's personalization surge. Watch for trial successes unlocking durable responses at scale, reinforcing its mission to accurately match therapies to patients.[1][2]
Acrivon Therapeutics has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series B in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $100.0M Series B | MPM Capital, RA Capital |